Clin2
NCT07298200Possibly a fitRecruiting

XH001 injection plus T-cells for advanced gastric cancer

Advanced Gastric Cancer

Treatments studied

Part of Cancer, Digestive system, Immune system & allergy clinical trials.

This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have advanced stomach cancer that has not responded to or you cannot tolerate standard treatments.
  • You have at least one tumor that can be measured on a scan, and your overall tumor size meets specific limits.
  • Your doctor expects you to live at least 12 weeks.
  • Your organs and bone marrow are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07329894Recruiting· Phase 1
XH001 and vaccine-activated T cells for advanced GI cancer

This trial tests a two-part treatment: an injection called XH001 plus a custom vaccine that trains your immune cells to attack tumors. It's for people with advanced stomach or bowel cancer that hasn't responded to at least two prior treatments.

Beijing
NCT07594964Recruiting· Phase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors

This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.

Beijing
NCT07333573Not yet recruiting· Phase 1/Phase 2
Hypoxia-targeted car-t cells for advanced gastric cancer

This trial tests a new type of immunotherapy called CAR-T cells that are designed to seek out and kill cancer cells in the low-oxygen environment of tumors. It is for people with advanced stomach cancer that has not responded to standard treatments.

Shanghai, Shanghai Municipality
NCT07114666Not yet recruiting
Vaccine XH001 plus chemo after pancreatic cancer surgery

This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.

Beijing
NCT06353646Recruiting
XH001 plus immunotherapy and chemotherapy after pancreatic cancer surgery

This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.

Beijing, Beijing Municipality
NCT07482319Not yet recruiting· Phase 1
Testing a new cell treatment for advanced solid tumors

This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.

Beijing

Hear when a new Advanced Gastric Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.